Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.40 |
| ▸ | CTSK | P43235 | 6/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | CPB1 | P15086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12658360 | 1.00 | CTSS (0.40) | CTSSCTSKCTSLCTSBCPB2 | |
| SCHEMBL12658361 | 0.91 | KLK7 (0.37) | CTSSCTSKCTSLCTSBCPB2 | |
| SCHEMBL13399241 | 0.90 | CPB2 (0.36) | CTSSCTSKCTSLCTSBCPB2 | |
| SCHEMBL13399706 | 0.90 | KLK7 (0.37) | CTSSCTSKCTSLCTSBCPB2 | |
| SCHEMBL3008889 | 0.89 | ITGB3 (0.45) | CPB2MAPK1CPB1 | |
| SCHEMBL13650201 | 0.89 | ITGB3 (0.45) | CPB2MAPK1CPB1 | |
| SCHEMBL3008885 | 0.89 | ITGB3 (0.45) | CPB2MAPK1CPB1 | |
| Benzene SCHEMBL29402026 | 0.88 | ACE (0.47) | CPB2MAPK1CPB1 | |
| SCHEMBL29800065 | 0.86 | CTSS (0.40) | CTSSCTSKCTSLCTSBKLK7 | |
| SCHEMBL29692878 | 0.86 | CTSS (0.40) | CTSSCTSKCTSLCTSBKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4532531-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | ScinoPharm Taiwan, Ltd. (TW) | 2025-04-09 | — | — | EP | claimed |
| US-20230406900-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | SCINOPHARM TAIWAN, LTD. (TW) | 2023-12-21 | — | — | US | claimed |
| WO-2023234860-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | SCINOPHARM TAIWAN LTD. (TW) | 2023-12-07 | — | — | WO | claimed |
| EP-4532531-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | ScinoPharm Taiwan, Ltd. (TW) | 2025-04-09 | — | — | EP | disclosed |
| EP-3728304-B1 | SOLID PHASE SYNTHESIS OF ACYLATED PEPTIDES | BACHEM HOLDING AG (CH) | 2025-02-12 | — | — | EP | disclosed |
| US-20230406900-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | SCINOPHARM TAIWAN, LTD. (TW) | 2023-12-21 | — | — | US | disclosed |
| WO-2023234860-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | SCINOPHARM TAIWAN LTD. (TW) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406900-A1 | PROCESS FOR PREPARING GLUCAGON-LIKE PEPTIDE-1 | GLP1R, IAPP, GCG | CTSS 4337/4885CTSK 3191/4885CTSL 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.